- Diagnostics
- Thursday, 09 Jul 2020
CooperRiis Launches New Insurance Driven Intensive Clinical Program
CooperRiis residential mental health treatment and healing community in Western North Carolina is pleased to introduce their new clinically intensive and insurance-driven CooperRiis at Asheville Program, opening September 1st, 2020. The CooperRiis at Asheville Program offers short-term treatment; 30-90 days, designed to promote stabilization and develop a foundation for a potential next step into its longer-term residential program on The CooperRiis Farm in Mill Spring.
The CooperRiis at Asheville Program integrates clinical services through psychiatry, individual and group therapy, and independent skill and functional recovery programming. The recovery program will benefit individuals in early recovery and individuals experiencing setbacks or recurrent mental health and substance use challenges.
The CooperRiis at Asheville Program treats adults 18 and over who experience mental health diagnoses such as anxiety, major depression, PTSD, bipolar disorder, schizophrenia, personality disorders, and any co-occurring condition related to addiction (dual diagnosis).
The CooperRiis at Asheville Program provides clinical services that will include psychotherapy, psychiatry, experiential group therapy, optimized medication use, psychoeducation, and 24-hour nursing. Evidenced-based group modalities are offered, such as Dialectical Behavioral Therapy (DBT), Acceptance and Commitment Therapy (ACT), Expressive Arts Therapy, and Psychosis Support.
The introduction of this new program is especially relevant today, as the COVID-19's emerging impact on society's mental health has been profound. The CooperRiis commitment to the principles of recovery provides an essential service for people whose emotional well-being has been further compromised by the pandemic.
"CooperRiis believes that with its focused attention, this program can help address the emerging societal complexity of the virus epidemic with this vulnerable population," Eric A. Levine, Ed.D, President and CEO.
Related Industry Updates
Huami partners with Nanshan Zhong's team to fight COVID-19 coronavirus in a joint laboratory
Apr 13, 2020
Cellulite Treatment: What Works and What You Should Know
Feb 19, 2026
OPKO Health's BioReference Laboratories in Partnership with New York State Initiates Testing for COVID-19 Antibodies
Apr 30, 2020
Diabetic Foot Ulcer Market: Exploring Growth, Innovations, and Patient Care by 2030
Nov 27, 2025
Quest Diagnostics Begins to Perform COVID-19 Antibody Testing
Apr 22, 2020
QiSant™ Initial Publication Demonstrates Strong Clinical Validation of Urine-Based Assay in Kidney Transplant Surveillance
Mar 19, 2020
Leader of leading Rare Disease Company (CENTOGENE) enters in the Finals of EY Entrepreneur of the Year 2019
Sep 23, 2019